Runyao Zhu

Runyao Zhu

Auto-generated profile, based on publicly available information

Runyao Zhu

Department of Chemical and Biomolecular Engineering University of Notre Dame Notre Dame Indiana USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2023 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
RZRunyao Zhu
Runyao Zhu
KMKamlesh M. Makwana
Kamlesh M. Makwana
YZYouwen Zhang
Youwen Zhang
BRBenjamin H. Rajewski
Benjamin H. Rajewski
JVJuan Del Valle
Juan Del Valle
YWYichun Wang
Yichun Wang
Graphene quantum dots with engineered properties are able to block the seeding activity of tau fibrils by inhibiting the fibrillization of monomeric tau and triggering the disaggregation of tau filaments.

28 March 2024 in Biophysical Journal
Verified
Journal Article
Closed access
RZRunyao Zhu
Runyao Zhu
TSTrevor Stone
Trevor Stone
YWYichun Wang
Yichun Wang

19 February 2026 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
GKGaeun Kim
Gaeun Kim
HJHyunsu Jeon
Hyunsu Jeon
ACAdrian Chao
Adrian Chao
JJJames Johnston
James Johnston
RZRunyao Zhu
Runyao Zhu
YWYichun Wang
Yichun Wang
Small extracellular vesicles (sEVs) have emerged as next‐generation multifunctional nanotherapeutics due to their parental‐cell traits and role in intercellular communication. Among them, immune cell–derived sEVs are uniquely positioned to couple innate immunomodulatory activities with therapeutic payload delivery, making them highly attractive for cancer therapy. In particular, M1 macrophage‐derived sEVs (M1‐sEVs) preserve the tumour‐suppressive functions of their parent cells, including tumour microenvironment (TME) reprogramming, immune activation, and inhibition of cancer progression. However, the mechanisms by which these activities are coordinated within the TME, and whether they act independently or synergistically, remain poorly understood. Clarifying these mechanisms is crucial for harnessing their intrinsic bioactivity in combination with their natural capacity as drug delivery nanocarriers to optimize therapeutic efficacy. Here, we demonstrate that M1‐sEVs exhibit intrinsic stability and circulation longevity via ‘do not eat me’ ligands, as well as tumour‐homing ability revealed by proteomic profiling, enabling efficient uptake and deep infiltration in breast cancer models. Functionally, M1‐sEVs deliver antiproliferative microRNAs that suppress tumour metabolism, growth, and progression by inhibiting self‐renewal, adhesion, migration, motility, and invasion. Importantly, by integrating this endogenous bioactivity with exogenous doxorubicin loading, we achieved synergistic efficacy: a 3‐fold reduction in IC 50 in vitro (0.46 µM vs. 1.45 µM for free drug) and 70.18% tumour growth inhibition in vivo. These findings highlight M1‐sEVs as dual‐action nanotherapeutics that combine innate immune‐regulatory and tumour‐inhibitory functions with efficient drug delivery, advancing their development as powerful platforms for cancer therapy.

22 July 2025 in Advanced NanoBiomed Research
Verified
Journal Article
Open access
RZRunyao Zhu
Runyao Zhu
GKGaeun Kim
Gaeun Kim
BRBenjamin H. Rajewski
Benjamin H. Rajewski
IAIsaac J. Angera
Isaac J. Angera
JVJuan Del Valle
Juan Del Valle
YWYichun Wang
Yichun Wang
Tauopathies, a group of neurodegenerative disorders, are characterized by the abnormal aggregation of tau proteins into neurofibrillary tangles, driving synaptic dysfunction, neuronal loss, and disease progression through tau aggregate propagation. Graphene quantum dots (GQDs) functionalized with D ‐cysteine ( D ‐GQDs) have shown promise in inhibiting tau aggregation and transmission via π–π stacking and electrostatic interactions with tau proteins. However, the nonspecific binding of GQDs to various proteins in the physiological environment, such as serum albumin, limits their clinical translation. In this study, the aim is to enhance the specificity of D ‐GQDs toward tau protein by incorporating a tau‐targeting N‐amino peptide, mxyl‐NAP2. The mxyl‐NAP2/ D ‐GQD complex demonstrates improved selectivity for tau protein over serum albumin, effectively enhancing the inhibition of tau aggregation. To further minimize off‐target effects and optimize therapeutic delivery, the mxyl‐NAP2/ D ‐GQD complex is loaded into small extracellular vesicles (sEVs), followed by functionalization of sEVs with neuron‐targeting ligand, rabies viral glycoprotein peptides. This strategy not only reduces off‐target effects, but also enhances uptake by neuron cells, which further improves inhibition of tau transmission between neurons. The results indicate that mxyl‐NAP2/ D ‐GQD‐sEVs hold great promise for overcoming the off‐target limitations of D ‐GQDs and advancing the development of precision therapeutics for neurodegenerative diseases.

22 October 2025 in bioRxiv
Verified
Preprint
Open access
GKGaeun Kim
Gaeun Kim
HJHyunsu Jeon
Hyunsu Jeon
ACAdrian Chao
Adrian Chao
JJJames Johnston
James Johnston
RZRunyao Zhu
Runyao Zhu
YWYichun Wang
Yichun Wang
Small extracellular vesicles (sEVs) have emerged as next-generation multifunctional nanotherapeutics due to their parental-cell traits and role in intercellular communication. Among them, immune cell–derived sEVs are uniquely positioned to couple innate immunomodulatory activities with therapeutic payload delivery, making them highly attractive for cancer therapy. In particular, M1 macrophage-derived sEVs (M1-sEVs) preserve the tumor-suppressive functions of their parent cells, including tumor microenvironment (TME) reprogramming, immune activation, and inhibition of cancer progression. However, the mechanisms by which these activities are coordinated within the TME, and whether they act independently or synergistically, remain poorly understood. Clarifying these mechanisms is crucial for harnessing their intrinsic bioactivity in combination with their natural capacity as drug delivery nanocarriers to optimize therapeutic efficacy. Here, we demonstrate that M1-sEVs exhibit intrinsic stability and circulation longevity via ‘do not eat me’ ligands, as well as tumor-homing ability revealed by proteomic profiling, enabling efficient uptake and deep infiltration in breast cancer models. Functionally, M1-sEVs deliver antiproliferative microRNAs that suppress tumor metabolism, growth, and progression by inhibiting self-renewal, adhesion, migration, motility, and invasion. Importantly, by integrating this endogenous bioactivity with exogenous doxorubicin loading, we achieved synergistic efficacy: a 3-fold reduction in IC 50 in vitro (0.46 μM vs. 1.45 μM for free drug) and 70.18% tumor growth inhibition in vivo . These findings highlight M1-sEVs as dual-action nanotherapeutics that combine innate immune-regulatory and tumor-inhibitory functions with efficient drug delivery, advancing their development as powerful platforms for cancer therapy.